Search - tctmd.com

Displaying 241 - 260 of 367

Sort: Relevancy | Date

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

News Daily News

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

Yael L. Maxwell

January 25, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Conference News WCC 2018

Is It Time to Loosen Restrictions on Saturated Fats and Salt?

Todd Neale

December 14, 2018

News Conference News WCC 2018

Rising CVD Threatens Middle East and North Africa

Todd Neale

December 13, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Daily News

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

Caitlin E. Cox

November 21, 2018

News Daily News

FDA Allows Claim About Oleic Acid’s Possible Heart Benefits on Labeling

Todd Neale

November 19, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

Advertisement

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Ethnic Variations in Lp(a) Concentrations Challenge Current Risk Thresholds

Top News in Clinical Cardiology: 2018

Top News in Prevention: 2018

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Is It Time to Loosen Restrictions on Saturated Fats and Salt?

Rising CVD Threatens Middle East and North Africa

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

FDA Allows Claim About Oleic Acid’s Possible Heart Benefits on Labeling

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content